article · Frontiers in Immunology
The AS01<sub>B</sub> adjuvant demonstrated superior IgG binding antibody and CD4+ T-cell responses compared with MF59 and Alum, when given with gp120 protein boost after ALVAC-HIV prime. These findings support AS01<sub>B</sub> as a superior adjuvant for HIV vaccine development, relative to MF59 and Alum.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3389/fimmu.2026.1768201
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
